89Zr-trastuzumab PET

Overview

89Zr-labeled trastuzumab PET/CT is a non-invasive whole-body imaging modality that measures HER2 receptor expression and heterogeneity in solid tumors. Avid lesions (SUV >= 10) indicate high uniform HER2 expression PMID:37406106.

Used by

• PMID:37406106 — 89Zr-trastuzumab PET/CT was performed on 8 patients with HER2-positive metastatic esophagogastric cancer in a phase II trial (NCT02954536); all 15 intensely avid lesions (SUV >= 10) decreased in size after a single dose of pembrolizumab + trastuzumab vs. only 9/32 non-intensely avid lesions (P = 2.4e-6); all 4 patients with >= 1 intensely avid lesion achieved 6-month PFS PMID:37406106.

Notes

• Uniform HER2 IHC 3+ and intense 89Zr-trastuzumab PET avidity (SUV >= 10) are complementary biomarkers for identifying patients most likely to benefit from HER2-directed therapy PMID:37406106.
• Corpus-grown slug; not present in canonical ontology.

Sources

• PMID:37406106

This page was processed by crosslinker on 2026-05-04.